Descriptive combination

COMBINATION PROFILE

pinealon-epitalon-dsip

Sources checked · October 16, 2026

Published for review · Scientific, medical, translation and citation review pending. Reported uses are not authorized indications. Frequency reflects mentions in supplied sources, not sales or global clinical prevalence.

Components

Community claim

Sleep, circadian and anti-aging claims.

Community and market provenance

Community mention, not clinical evidence

    Evidence of the exact combination

    No controlled clinical validation of this exact marketed combination was established in this review. Ingredient evidence is not combination evidence.

    Component links are not combination evidence. A commercial name’s composition may vary.

    Uncertainty and risks

    Reports may describe sequential use rather than simultaneous combinations; no validated clinical interaction profile.

    Observed in supplier/community material; prevalence not quantified.

    No dosing or mixing instructions are provided.

    Source issues and references

    References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.

    1. PMID1299794

      Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study.

      Bes F, Hofman W, Schuur J, Van Boxtel C.

      October 16, 2026

    2. PMID21978084

      Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes.

      Khavinson V, Ribakova Y, Kulebiakin K, Vladychenskaya E, Kozina L, Arutjunyan A, Boldyrev A.

      October 16, 2026

    3. PMID26390612

      [EFFECT OF SYNTHETIC PEPTIDES ON AGING OF PATIENTS WITH CHRONIC POLYMORBIDITY AND ORGANIC BRAIN SYNDROME OF THE CENTRAL NERVOUS SYSTEM IN REMISSION].

      Meshchaninov VN, Tkachenko EL, Zharkov SV, Gavrilov IV, Katyreva IuE.

      October 16, 2026

    4. PMID41240216

      Correction: Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity.

      Al-Dulaimi S, Thomas R, Matta S, Roberts T.

      October 16, 2026

    5. R06

      FDA: current bulk-substance safety-risk page

    6. R18

      Bes et al.: DSIP insomnia trial, 1992

    7. R24

      Al-Dulaimi et al.: Epitalon in cell lines, 2025

    A community-based bilingual scientific education initiative for healthcare professionals and the general public across the Americas.Currently self-funded; no current sponsors. Formal governance and legal documentation pending.info@peptideamericas.org · Planned contact address — not active yet; please do not send messages.